

SENATE No. 660

The Commonwealth of Massachusetts

PRESENTED BY:

John F. Keenan

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act relative to the care and treatment of patients with mitochondrial disease.

PETITION OF:

NAME:

John F. Keenan

DISTRICT/ADDRESS:

Norfolk and Plymouth

SENATE No. 660

By Mr. Keenan, a petition (accompanied by bill, Senate, No. 660) of John F. Keenan for legislation relative to the care and treatment of patients with mitochondrial disease. Financial Services.

[SIMILAR MATTER FILED IN PREVIOUS SESSION
SEE SENATE, NO. 689 OF 2021-2022.]

The Commonwealth of Massachusetts

**In the One Hundred and Ninety-Third General Court
(2023-2024)**

An Act relative to the care and treatment of patients with mitochondrial disease.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

1 SECTION 1. Chapter 32A of the General Laws, as appearing in the 2020 Official
2 Edition, is hereby amended by inserting after section 17R the following section:-

3 Section 17S. The commission shall provide to any active or retired employee of the
4 commonwealth or spouse/dependent who is insured under the group insurance commission
5 coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited
6 to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin
7 C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.

8 SECTION 2. Chapter 175 is hereby amended by inserting after section 47NN the
9 following section:-

10 Section 4700. Any policy, contract, agreement, plan or certificate of insurance issued,
11 delivered or renewed within the commonwealth shall provide coverage for treatment of
12 mitochondrial disease. Said treatment shall include, but not be limited to, the use of vitamin and
13 nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin B1, Vitamin
14 B2, Vitamin K1 and L-Carnitine.

15 SECTION 3. Chapter 176A is hereby amended by inserting after Section 800 the
16 following section:-

17 Section 8PP. Any contract between a subscriber and a corporation under an individual or
18 group hospital service plan delivered, issued or renewed within the commonwealth shall provide
19 coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited
20 to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin
21 C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.

22 SECTION 4. Chapter 176B is hereby amended by inserting after section 400 the
23 following section:-

24 Section 4PP. Any subscription certificate under an individual or group medical service
25 agreement delivered, issued or renewed within the commonwealth shall provide coverage for
26 treatment of mitochondrial disease. Said treatment shall include, but not be limited to, the use of
27 vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin
28 B1, Vitamin B2, Vitamin K1 and L-Carnitine.

29 SECTION 5. Chapter 176G is hereby amended by inserting after Section 4GG the
30 following section:-

31 Section 4HH. Any individual or group health maintenance contract shall provide
32 coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited
33 to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin
34 C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.